• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

PerkinElmer completes Oxford Immunotec acquisition

March 9, 2021 By Sean Whooley

PerkinElmer oxford immunotecPerkinElmer (NYSE:PKI) announced today that it completed its previously announced acquisition of Oxford Immunotec.

Under the acquisition agreement announced in January, London-based Oxford Immunotec’s shareholders will be entitled to receive $22 for each outstanding ordinary share, with the terms of the acquisition valuing Oxford Immunotec’s entire issued and to-be-issued ordinary share capital at $591 million.

The terms of the acquisition include a premium of approximately 28.3% to the closing price of $17.15 per share on Jan. 5, 2021 and 53.5% to the 90-trading-day volume-weighted average of $14.34 during the period of Oct. 8, 2020, to Jan. 5, 2021.

Oxford Immunotechad approximately 275 global employees as of Sept. 30, 2020, with reported revenues of $73.7 million and $39.2 million from continuing operations as of the fiscal year ended Dec. 31, 2019 and the nine months ended Sept. 30, 2020, respectively, according to a news release.

Waltham, Mass.-based PerkinElmer expects the acquisition of Oxford Immunotec to be “modestly accretive” to its non-GAAP earnings in the first year after close. The company anticipates that Oxford Immunotec’s sales growth will exceed that of its diagnostics franchise for the foreseeable future.

PerkinElmer said the acquisition will help to grow its portfolio of advanced infectious disease testing solutions to include tuberculosis detection while enabling the company to combine its channel expertise and workflow and testing capabilities with Oxford Immunotec’s capabilities in the space of T-cell immunology.

“Oxford Immunotec’s global role in fighting tuberculosis, particularly its trademark product, the T-SPOT.TB test, and the operations it has built are remarkable,” PerkinElmer president & CEO Prahlad Singh said in the release. “We recognize the distinct clinical and logistical advantages of the test and see a great opportunity to leverage our automation capabilities and commercial channel access to bring tuberculosis testing to more customers around the world.”

Filed Under: Business/Financial News, Diagnostics, Drug-Device Combinations, Featured, Mergers & Acquisitions, Respiratory Tagged With: Oxford Immunotec, perkinelmer

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS